<--- Back to Details
First PageDocument Content
Tetrazoles / Combination drugs / Imidazoles / Carboxylic acids / Valsartan / Hydrochlorothiazide / Olmesartan / Telmisartan/hydrochlorothiazide / Candesartan / Chemistry / Organic chemistry / Angiotensin II receptor antagonists
Date: 2013-10-01 07:59:27
Tetrazoles
Combination drugs
Imidazoles
Carboxylic acids
Valsartan
Hydrochlorothiazide
Olmesartan
Telmisartan/hydrochlorothiazide
Candesartan
Chemistry
Organic chemistry
Angiotensin II receptor antagonists

Kansas Medical Assistance Program P O Box 3571 Topeka, KS[removed]Provider[removed]Beneficiary[removed]

Add to Reading List

Source URL: www.kdheks.gov

Download Document from Source Website

File Size: 121,94 KB

Share Document on Facebook

Similar Documents

EZ-SCREEN® CUP Package Insert-II The EZ-SCREEN® Cup products are rapid qualitative screening assays for the detection of any combination of the following drugs or their metabolites in human urine: Amphetamine, Barbitu

DocID: 1vnGd - View Document

SCUDEM 2017 Problem B - Drug Interactions Patients undergoing medical treatment may be given a combination of drug therapies, and the information about the interaction between drugs can be limited[1]. One commonly prescr

DocID: 1uSqq - View Document

Gilead Sciences / Chemistry / HIV/AIDS / Medicine / Organofluorides / Specialty drugs / Prodrugs / Prevention of HIV/AIDS / AIDS Healthcare Foundation / Tenofovir alafenamide / Tenofovir disoproxil / Fixed-dose combination

Case 3:16-cvDocument 1 FiledPage 1 ofDorian S. Berger, CA State Bar NoDaniel P. Hipskind, CA State Bar No

DocID: 1rqYi - View Document

Chemistry / Organic chemistry / Combination drugs / RTT / Diuretics / Thiazides / Sulfonamides / AstraZeneca / Atenolol/chlorthalidone / Candesartan / Budesonide/formoterol / Hydrochlorothiazide

As at AugustAstraZeneca’s Environmental Risk Summaries As part of AstraZeneca’s ongoing commitment to environmental data transparency, this website provides environmental risk summaries for the Active Pharmace

DocID: 1rlq4 - View Document

Clinical medicine / Medicine / Cancer / Antineoplastic drugs / Cancer treatments / Signal transduction / Breast cancer / Macrolides / Eribulin / Halichondrin B / MTOR inhibitors / Eisai

EISAI AND PIQUR SIGN LANDMARK COLLABORATION AGREEMENT TO INVESTIGATE HALAVEN® (ERIBULIN) AND PQR309 IN HARD TO TREAT FORM OF BREAST CANCER Agreement will see eribulin used in combination with novel PI3K/mTOR inhibitor i

DocID: 1rhhk - View Document